Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The levels of serum gamma-glutamyl transpeptidase (GGT) and, when appropriate, alkaline phosphatase (AP) and 5'-nucleotidase (NTD) have been measured as a routine in 276 patients with malignant haematological diseases during a 26-month trial period. GGT levels add no prognostic information to the routine haematological surveillance of leukaemia. Polychemotherapy does not appear to be an inducer of liver drug-metabolising microsomal enzymes. Polycythaemia rubra vera, myelofibrosis and chronic lymphocytic leukaemia may cause little change in GGT, AP and NTD levels despite marked hepatomegaly. A raised GGT in Hodgkin's disease and non-Hodgkin lymphoma is generally associated with active and widespread disease, but not necessarily a sign of malignant tissue in the liver. The elevations of GGT in myeloma may be secondary to liver infiltration though this group merits further detailed study.
 ...
PMID:Evaluation of the usefulness of serum gamma-glutamyl transpeptidase levels in the management of haematological neoplasia. 2 19

Possibilities and limits of radiotherapy are described in a survey in the following diseases: Undifferentiated cell leucoses: The radiotherapy of the central nervous system brings an increase of the 5-year survival rates, since the localisations in this region existing in 45-70% are only insufficiently reached by the cytostatic substances because of the defective blood-liquor passage. On the other hand, other indications to radiotherapy recede into the background. Chronic leucoses: In the foreground of the application is the ray-therapy of the spleen, of which, apart from the local effect on the splenic tumour, also an improvement of the remission rates is expected. At adequate indication also the ray-therapy of infiltrates in the lymph nodes and other localisations achieves good palliative results. The extra-corporeal irradiation of blood is a method, the usability of which must still be proved. With the introduction of the modern cytostatic drugs the exposure of the whole body has lost significance. Lymphogranulomatosis: In this disease the radiotherapy has caused a decisive change: In these cases the recognition of the local development of the disease and its continuous spreading was decisive, and issuing from this also the simultaneous irradiation of the defluxion areas and the application of an oncolytic dose. According to the stage with or without combination of cytostatic drugs an exact plan of therapy is made. Here healing rates of 70-80% in stage I are to be expected. Myeloma: Here the radiotherpy has palliative tasks, with correct indication good effects are to be expected. Polycythaemia vera: In this disease radiotherapy in form of incorporation of radioactive phosphorus is the remedy of choice.
 ...
PMID:[Radiotherapy of hematologic diseases]. 6 Aug 34

The diagnostic value of the Alkaline Leucocyte Phosphatase (ALP) was checked on the basis of the patients of a hematologic department. Reliable data can only be obtained for the differential diagnosis of polycythemia vera and secondary polycythemia, not however for the differential diagnosis of chronic myeloid leukemia (CML) and myelofibrosis. In CML the ALP is an aid for evaluating the course of the disease and its remissions. In Hodgkin's disease it is an objective parameter for actiivty of the disease. The leucocyte concentration method can be used for evaluation of the ALP.
 ...
PMID:[Diagnostic value of alkaline leucocyte phosphatase in hematology (author's transl)]. 28 25

Among 246 patients (49 with Hodgkin's disease, 29 with multiple myeloma, 75 with other lympho- and immunoproliferative syndromes, 70 with carcinomas and 23 with non-malignant affections) treated by cytostatic or immunosuppressive chemotherapy, 6 developed malignant hemopathy (acute myeloblastic leukemia, erythroleukemia and erythremia) apparently induced during the last 7 1/2 years. In addition, 2 carcinomas have been noted. All have received melphalan or chlorambucil, alone or associated with other cytostatic drugs. 5 out of these 6 patients also underwent radiotherapy. The lenght of chemotherapy ranged between 7 and 110 months and the latency between 45 and 110 months. A "preleukemic" cytopenia phase was observed in 4 out of 6 cases. An exceptional 45-month survival was secured in case 1 (acute myeloblastic leukemia in a patient probably cured of Hodgkin's disease IIIB). Observation 2 is the 3rd case ever published of induced acute leukemia in disseminated lupus erythematosus. All these observations are compared with the latest findings in the literature. To the very extent that the utilization of cytostatic drugs produces improvement in the prognosis of very serious diseases, their leukemogenic potential becomes more dangerous and demands limitation of their use.
 ...
PMID:[Induced malignant hemopathies. 6 new cases with 1 patient surviving 45 months]. 28 15

A patient with polycythemia vera received a moderate dose (480 mg) of busulfan intermittently over a 6 year period and later developed Hodgkin's disease. Following split-course upper mantle, chest irradiation, he developed rapidly progressive, fatal pneumonia and bone marrow hypoplasia. It is postulated that the hyperacute organ failures (lung and bone marrow) resulted from augmentation of subclinical busulfan-induced damage of these organs by additive radiation effect. It is recommended that in patients who have had antineoplastic chemotherapy, major radiotherapy to the cervicothoracic region be accompanied by careful monitoring of respiratory and hematopoietic function, both before and during radiotherapy.
 ...
PMID:Fatal radiation pneumonia following subclinical busulfin injury. 40 75

32P is effective therapy for polycythemia and primary thrombocytosis. The Polycythemia Vera Study Group is comparing radioactive phosphorus with alkylating agents to determine relative efficacy. Less well investigated is the effectiveness of 32P vs. busulfan in chronic granulocytic leukemia. Endolymphatic administration of radiopharmaceuticals may play a role in the therapy of infradiaphragmatic lymphoma. Among the radionuclides that have at times been used in hematology are 32P, 198Au 24Na, 76As, 89Sr, 52Mb, 54Mn, 91Y, 95Zr, 95Cb, 111Ag, 109Pd, 131I, 185W, and 192Ir. As stated, 32P has proven single most efficacious agent. The hematologic diseases that have been treated include both malignant and benign conditions. Among the malignant conditions are polycythemia vera, agnogenic myeloid metaplasia, thrombocythemia, leukemia, Hodgkin's disease, and multiple myeloma. Hemophilia, and Osler--Weber--Rendu disease are among the benign entities in which the agents have been tried. Polycythemia and thrombocythemia remain those in which the greatest success has been achieved.
 ...
PMID:Radionuclide therapy of hematologic disorders. 48 47

Ionizing radiation used for diagnosis or therapy has been associated with an increased incidence of malignancies of blood-forming organs. The increased incidence of hematopoietic malignancies following exposure to ionizing radiation obtained in the course of occupation, diagnosis and therapy of disease, or as a weapon of war is documented. The natural occurrence and the induced progression to acute leukemia of polycythemia rubra vera, Hodgkin's disease, multiple myeloma, Di Guglielmo's disease, and reticuloendothelial malignancies are discussed. The status of transplantation and immunodeficiency states and their relationship to acute leukemia is reviewed. Finally, drugs, toxins, and the use of cytotoxic radiomimetic agents for nonmalignant purposes are shown to lead to the development of acute leukemia. Background information relevant to the proper use of future diagnostic and therapeutic modalities is provided.
 ...
PMID:Malignancies in blood-forming organs following diagnostic and therapeutic procedures: a review. 106 32

Study on the genealogy of 671 patients with hemoblastosis has evidenced a more frequent incidence of malignant neoplasms in the families of patients with chronic lympholeucosis, erythremia and lymphogranulomatosis compared with the families of practically healthy persons. Whereas this regularity is not revealed in the families of patients with acute forms of leucosis and chronic myeloleucosis.
 ...
PMID:[Hereditary predisposition to oncological diseases in leukemia patients]. 106 2

Chromosomal findings are reported in three patients with acute myelomonocytic leukemia and in one with reticulosarcoma leukemia who had been treated for multiple myeloma with melphalan and X-ray. All four patients had striking chromosomal anomalies. An iatrogenic causation of aneuploidy is suggested. This is supported by chromosomal findings in patients with acute leukemia following polycythemia vera and Hodgkin's disease; practically all of the leukemias have been aneuploid. A comparison is made of such "secondary" acute leukemias with "primary" acute leukemias that are aneuploid in only 40% of the cases. Chromosomal changes are not considered to be the initial event in leukemogenesis.
 ...
PMID:Chromosome studies in acute leukemias developing in patients with multiple myeloma. 109 66

Recent studies have generated data demonstrating significant clinical activity of alpha-interferon therapy in each of six hematological malignancies, chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphomas, multiple myelomatosis and hairy cell leukaemia.
 ...
PMID:alpha-Interferon in hematological malignancies. 136 59


1 2 3 4 5 Next >>